Literature DB >> 18763416

Increasing transparency at the FDA: the impact of the FDA Amendments Act of 2007.

Susan F Wood1, Kristen L Perosino.   

Abstract

Mesh：

Year:  2008        PMID： 18763416      PMCID： PMC2430650          DOI： 10.1177/003335490812300415

Source DB:  PubMed          Journal:  Public Health Rep        ISSN： 0033-3549            Impact factor:   2.792


× No keyword cloud information.
  4 in total

1.  Financial conflict of interest disclosure and voting patterns at Food and Drug Administration Drug Advisory Committee meetings.

Authors:  Peter Lurie; Cristina M Almeida; Nicholas Stine; Alexander R Stine; Sidney M Wolfe
Journal:  JAMA       Date:  2006-04-26       Impact factor: 56.272

2.  Bolstering the FDA's drug-safety authority.

Authors:  William B Schultz
Journal:  N Engl J Med       Date:  2007-11-29       Impact factor: 91.245

3.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

Authors:  Steven E Nissen; Kathy Wolski
Journal:  N Engl J Med       Date:  2007-05-21       Impact factor: 91.245

4.  Selective publication of antidepressant trials and its influence on apparent efficacy.

Authors:  Erick H Turner; Annette M Matthews; Eftihia Linardatos; Robert A Tell; Robert Rosenthal
Journal:  N Engl J Med       Date:  2008-01-17       Impact factor: 91.245
  4 in total
  1 in total

1.  The FDA responds.

Authors:  Randall Lutter; William A McConagha
Journal:  Public Health Rep       Date:  2008 Jul-Aug       Impact factor: 2.792
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.